ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 291

Factors Explaining Patient Perspective in Psoriasis and Psoriatic Arthritis: The Role of Inflammation and Structural Damage Detected by Ultrasound

Tania Gudu1, Ilaria Padovano 1, Hélène Gouze 2, François Vidal 1, Emmanuel Mahé 3, Leire Lara Gonzalez 4, Alexis Guyot 4, Philippe Saiag 4, Isabelle Bourgault Villada 4, Sophie Ruel-Gagné 1, Gilles Hayem 1, Félicie Costantino 5, Maxime Breban 6 and Maria-Antonietta D’Agostino 7, 1Rheumatology Department, APHP, Ambroise Paré Hospital, Boulogne Billancourt, France, 2Rheumatology Department, APHP, Ambroise Paré Hospital, Bolougne Billancourt, France, 3Dermatology Department, Victor Dupouy Hospital, Argenteuil, France, 4Dermatology Department, Ambroise Paré Hospital, Boulogne Billancourt, France, 5UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, 6UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, 7Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: patient outcomes and ultrasound, psoriasis, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Imaging Of Rheumatic Diseases Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient reported outcomes (PROs) reflect patients’ opinion on disease activity, impact of disease, quality of life (QoL), disability and are essential in the assessment of PsA patients. PROs may be influenced by several factors other than disease activity and severity. US is an objective tool to evaluate inflammation and structural damage in PsA. This cross-sectional study aimed at evaluating the role of US-detected inflammation (synovitis, tenosynovitis, enthesitis, dactylitis) and structural damage (erosions, enthesophytes, osteophytes and cortical irregularities), according to the OMERACT definitions and scoring [1], to explain PROs in PsA and to compare that to psoriasis (PsO) patients with and without musculoskeletal (MSK) symptoms.

Methods: PsA (CASPAR criteria) [2], PsO with MSK symptoms without fulfilling CASPAR criteria (symptoPsO) and PsO with no MSK symptoms (asymptoPsO) were included. Socio-demographic characteristics, comorbidities, disease duration and treatment were collected. All patients underwent dermatological and rheumatologic assessment: PsO severity, swollen joint count (SJC), tender JC (TJC), number of dactylitis and enthesitis, fibromyalgia criteria; and US evaluation on joints, tendons and entheses as shown in figure 1. PROs were evaluated in all patients: assessment of skin psoriasis and of fatigue on a numeric rating scale (NRS), HAQ and QoL assessed by SF36. Variables were compared across groups (chi square or one-way ANOVA test). Correlations were evaluated using Spearman’s test.

Results: One hundred fifty eight patients (54 PsA, 52 symptoPsO and 52 asymptoPsO) with similar socio-demographic characteristics and PsO duration were included (table 1). Most of PsA patients had low/moderate disease activity. With the exception of US enthesophytes, all US changes were significantly higher in PsA, followed by symptoPsO patients.

Across all 3 groups, all PROs correlated mainly with demographic variables, comorbidities, TJC, number of enthesitis, skin severity, depression and fibromyalgia (r=0.29-0.66). SymptoPsO and PsA reported similar scores of fatigue and impact on some QoL domains (vitality, pain, general health, social and mental), significantly higher than asymptoPsO. Only in PsA, HAQ correlated with the total number of US enthesitis (r=0.35, p=0.01) and of joints with ostheophytes/cortical irregularities (r=0.28, p=0.04) as well as the physical function domain of SF36 with the number of joints with ostheophytes/cortical irregularities (r=-0.33, p=0.02).

Conclusion: Quality of life, disability and fatigue were more impaired in PsA and symptoPsO patients than asymptoPsO. In all groups, PROs were mostly associated with socio-demographic characteristics, comorbidities and some clinical variables rather than objective measures such as US changes.

Acknowledgement: The study was supported by a grant from The PARTNER Psoriatic Arthritis Network fellowship.

References:

  1. Bruyn GA et al. J Rheumatol 2019 

  1. Taylor W et al. Arthritis Rheum 2006

Figure 1. Anatomical sites of US evaluation: joints, entheses and tendons


table 1

Table 1. Characteristics of the patients included in the 3 groups: PsA patients, patients with psoriasis with MSK symptoms -symptoPsO- and patients with psoriasis and no MSK symptoms -asymptoPsO-

PsA: psoriatic arthritis; PsO: psoriasis; PASI: Psoriasis Area and Severity Index; TJC: total tender joint count; SJC: total swollen joint count; N: number; SD: standard deviation; NRS: numeric rating scale; SF36: Medical Outcome Study Short Form-36; PF: Physical Functioning; RP: Physical Role functioning; BP: Bodily Pain; GH: General Health; VT: Vitality; SF: Social role Functioning; MH: Mental Health; RE: Emotional Role functioning
* Number of enthesitis was calculated according to the Spondyloarthritis Research Consortium of Canada -SPARCC- Enthesitis Index


Disclosure: T. Gudu, None; I. Padovano, None; H. Gouze, None; F. Vidal, None; E. Mahé, None; L. Lara Gonzalez, None; A. Guyot, None; P. Saiag, None; I. Bourgault Villada, None; S. Ruel-Gagné, None; G. Hayem, None; F. Costantino, None; M. Breban, None; M. D’Agostino, None.

To cite this abstract in AMA style:

Gudu T, Padovano I, Gouze H, Vidal F, Mahé E, Lara Gonzalez L, Guyot A, Saiag P, Bourgault Villada I, Ruel-Gagné S, Hayem G, Costantino F, Breban M, D’Agostino M. Factors Explaining Patient Perspective in Psoriasis and Psoriatic Arthritis: The Role of Inflammation and Structural Damage Detected by Ultrasound [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/factors-explaining-patient-perspective-in-psoriasis-and-psoriatic-arthritis-the-role-of-inflammation-and-structural-damage-detected-by-ultrasound/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-explaining-patient-perspective-in-psoriasis-and-psoriatic-arthritis-the-role-of-inflammation-and-structural-damage-detected-by-ultrasound/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology